PREMPHASE 14/14 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Premphase 14/14, and what generic alternatives are available?
Premphase 14/14 is a drug marketed by Wyeth Pharms and is included in one NDA.
The generic ingredient in PREMPHASE 14/14 is estrogens, conjugated; medroxyprogesterone acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estrogens, conjugated; medroxyprogesterone acetate profile page.
Summary for PREMPHASE 14/14
Pharmacology for PREMPHASE 14/14
| Drug Class | Estrogen Progestin |
| Mechanism of Action | Estrogen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for PREMPHASE 14/14
US Patents and Regulatory Information for PREMPHASE 14/14
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PREMPHASE 14/14
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Wyeth Pharms | PREMPHASE 14/14 | estrogens, conjugated; medroxyprogesterone acetate | TABLET;ORAL-28 | 020527-002 | Nov 17, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PREMPHASE 14/14
See the table below for patents covering PREMPHASE 14/14 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 042262 | USO DE 8,9-DIHIDROESTRONA PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ATEROSCLEROSIS | ⤷ Try a Trial |
| Hong Kong | 1020282 | ⤷ Try a Trial | |
| Australia | 2007697 | ⤷ Try a Trial | |
| Singapore | 33663 | Novel sugar coating composition for application to compressed medicinal tablets | ⤷ Try a Trial |
| Hungary | 9603151 | ⤷ Try a Trial | |
| Iceland | 4385 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PREMPHASE 14/14
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0136011 | SPC/GB02/008 | United Kingdom | ⤷ Try a Trial | SPC/GB02/008: 20040802, EXPIRES: 20090801 |
| 0136011 | SPC/GB97/032 | United Kingdom | ⤷ Try a Trial | SPC/GB97/032: 20040802, EXPIRES: 20090801 |
| 0136011 | 99C0003 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306 |
| 0136011 | C00136011/03 | Switzerland | ⤷ Try a Trial | PRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417 |
| 0136011 | 2000C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| 0136011 | SPC/GB98/034 | United Kingdom | ⤷ Try a Trial | SPC/GB98/034: 20040802, EXPIRES: 20090801 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
